{'Year': '2018', 'Month': 'Apr'}
Clinical Outcomes and Sustainability of Using <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
<i>CYP2C19</i> loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability, and clinical impact of using <i>CYP2C19</i> genotype-guided dual antiplatelet therapy (DAPT) selection in practice remains unclear.